

May 6, 2026

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress.

Conference Call and Webcast Information:

- Date: Tuesday, May 12, 2026 at 4:30 PM ET
- Participant Dial-in (US): 1-800-717-1738
- Participant Dial-in (International): 1-646-307-1865
- Webcast Access: [Click Here](#)

A replay of the webcast will be available in the Investors section of the Relmada website at <https://www.relmada.com/investors/ir-calendar>.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:

Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications
media@relmada.com



Source: Relmada Therapeutics